The GnRH receptor antagonist, degarelix, approved for the treatment of advanced prostate cancer (Firmagon®), was investigated as an alternative medical approach for the treatment of moderate-to-severe BPH-LUTS in patients without prostate cancer. Here, GNRHR is linked to prostate cancer.